Z160: Completed Phase IIa enrollment

Zalicus completed enrollment of about 140 patients with PHN in a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 375 mg

Read the full 213 word article

How to gain access

Continue reading with a
two-week free trial.